Abstract
Several molecular and genetic studies have provided new perspectives on the histologic classification of bladder tumors. Recent developments in the field of molecular mutational pathway analyses based on next generation sequencing technology together with classic data derived from the description of mutations in the FGFR3 (fibroblast growth factor receptor 3) gene, mutations on TP53 gene, and cDNA technology profiling data gives support to a differentiated taxonomy of bladder cancer. All these changes are behind the use of non-traditional approach to therapy of bladder cancer patients and are ready to change our daily practice of uro-oncology. The observed correlation of some molecular alterations with tumor behavior and the identification of their targets at cellular level might support the use of molecular changes together with morphological data to develop new clinical and biological strategies to manage patients with urothelial cancer. The current review provides comprehensive data to support personalized therapy for bladder cancer based on an integrated approach including pathologic and clinical features and molecular biology.
Keywords: Bladder cancer, genito-urinary cancers, molecular pathology, personalized therapy, precision oncology, targeted therapy.
Current Drug Targets
Title:Bladder Cancer: Molecular Determinants of Personalized Therapy
Volume: 16 Issue: 2
Author(s): Antonio Lopez-Beltran, Matteo Santoni, Francesco Massari, Chiara Ciccarese, Giampaolo Tortora, Liang Cheng, Holger Moch, Marina Scarpelli, Carlos Reymundo and Rodolfo Montironi
Affiliation:
Keywords: Bladder cancer, genito-urinary cancers, molecular pathology, personalized therapy, precision oncology, targeted therapy.
Abstract: Several molecular and genetic studies have provided new perspectives on the histologic classification of bladder tumors. Recent developments in the field of molecular mutational pathway analyses based on next generation sequencing technology together with classic data derived from the description of mutations in the FGFR3 (fibroblast growth factor receptor 3) gene, mutations on TP53 gene, and cDNA technology profiling data gives support to a differentiated taxonomy of bladder cancer. All these changes are behind the use of non-traditional approach to therapy of bladder cancer patients and are ready to change our daily practice of uro-oncology. The observed correlation of some molecular alterations with tumor behavior and the identification of their targets at cellular level might support the use of molecular changes together with morphological data to develop new clinical and biological strategies to manage patients with urothelial cancer. The current review provides comprehensive data to support personalized therapy for bladder cancer based on an integrated approach including pathologic and clinical features and molecular biology.
Export Options
About this article
Cite this article as:
Lopez-Beltran Antonio, Santoni Matteo, Massari Francesco, Ciccarese Chiara, Tortora Giampaolo, Cheng Liang, Moch Holger, Scarpelli Marina, Reymundo Carlos and Montironi Rodolfo, Bladder Cancer: Molecular Determinants of Personalized Therapy, Current Drug Targets 2015; 16 (2) . https://dx.doi.org/10.2174/1389450116666150204115756
DOI https://dx.doi.org/10.2174/1389450116666150204115756 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Chaperone Hsp90 as a Target for Oxidant-Based Anticancer Therapies
Current Medicinal Chemistry Power from the Garden: Plant Compounds as Inhibitors of the Hallmarks of Cancer
Current Medicinal Chemistry Surgical Treatment in FIGO Stage I Cervical Cancer: Evolution of Concepts
Current Women`s Health Reviews Glyco-Nanomaterials: Translating Insights from the “Sugar-Code” to Biomedical Applications
Current Medicinal Chemistry Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Recent Patents on Anti-Cancer Drug Discovery TRP Channels as Therapeutic Targets in Kidney Disease and Hypertension
Current Topics in Medicinal Chemistry Multifunctional Anti-Cancer Nano-Platforms are Moving to Clinical Trials
Current Drug Metabolism Evaluation of the Oxidative Stress Level and Serum Prolidase Activity in Patients with Sleep Bruxism
Combinatorial Chemistry & High Throughput Screening The Radionuclide Molecular Imaging and Therapy of Neuroendocrine Tumors
Current Cancer Drug Targets The Role of Neuroendocrine Cells in Prostate Cancer: A Comprehensive Review of Current Literature and Subsequent Rationale to Broaden and Integrate Current Treatment Modalities
Current Medicinal Chemistry Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets Patents on Immunotoxins and Chimeric Toxins for the Treatment of Cancer
Recent Patents on Drug Delivery & Formulation In-Silico Analysis of rSNPs in miRNA:mRNA Duplex Involved in Insulin Signaling Genes Shows a Possible Pathogenesis of Insulin Resistance
MicroRNA Open Architecture PCR-Based Methods for Differential Gene Expression Analysis
Current Pharmaceutical Analysis Contribution of Latin American Countries to Cancer Research and Patent Generation: Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Anti-cancer Peptides from Ras-P21 and P53 Proteins
Current Pharmaceutical Design Clinical Considerations in Developing Dendritic Cell Vaccine Based Immunotherapy Protocols in Cancer
Current Molecular Medicine Thermodynamics and Electro-Biologic Prospects for Therapies to Intervene in Cancer Progression
Current Cancer Therapy Reviews Cell Hierarchy, Metabolic Flexibility and Systems Approaches to Cancer Treatment
Current Pharmaceutical Biotechnology The Role of Capecitabine in the Management of Tumors of the Digestive System
Reviews on Recent Clinical Trials